Publicaties
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis KU Leuven
Mesalamine Once Daily Is More Effective Than Twice Daily in Patients With Quiescent Ulcerative Colitis KU Leuven
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis KU Leuven
Mesalazine-induced eosinophilic glossitis and hypereosinophilia in a patient with ulcerative colitis Vrije Universiteit Brussel
A 74-year-old male, with a four-year history of ulcerative colitis (UC) treated with mesalazine, presented with episodic cheek and progressive tongue swelling respectively since 27 months. History revealed nocturnal sweating, difficulties swallowing solid food, loss of appetite and weight. There was no fever or atopy.
Chronic Sulfasalazine Treatment in Mice Induces System xc- - Independent Adverse Effects Vrije Universiteit Brussel KU Leuven
Despite ample evidence for the therapeutic potential of inhibition of the cystine/glutamate antiporter system xc- in neurological disorders and in cancer, none of the proposed inhibitors is selective. In this context, a lot of research has been performed using the EMA- and FDA-approved drug sulfasalazine (SAS). Even though this molecule is already on the market for decades as an anti-inflammatory drug, serious side effects due to its use have ...